| abstract |
The present application relates to mutant interleukin-2 polypeptides. The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity for the IL-2 receptor alpha subunit for use as immunotherapeutics. In addition, the present invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding mutant IL-2 polypeptides or immunoconjugates, and vectors and hosts comprising such polynucleotide molecules cell. The present invention further relates to methods for producing said mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising said mutant IL-2 polypeptides or immunoconjugates, and uses thereof. |